EVALUATION OF PDE 5 ON ENDOTHEIAL ACTIVITY BY ACETYLCHOLINE IONTOPHORESIS

乙酰胆碱离子电渗疗法评价 PDE 5 的内皮活性

• 批准号: 7724972
• 负责人: Arnost Fronek
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724972
• 关键词: Acetylcholine; Computer Retrieval of Information on Scientific Projects Database; Cyclic GMP; Diabetes Mellitus; Evaluation; Funding; Grant; Guanine Nucleotides; Hypertension; Institution; Invasive; Iontophoresis; Patients; Peripheral arterial disease; Pharmaceutical Preparations; Play; Research; Research Personnel; Resources; Risk Factors; Source; System; Testing; United States National Institutes of Health; Vascular System; cardiovascular risk factor; hypercholesterolemia; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1. The enod thelium is a vital component of the vascular system and it has been documented that it plays a vital roel in the control of cardiovascular risk factors (1). Phosphodistrerase type 5 (PDE 5)substances have been shown that by inactivating cyclic guanosine phosphates (cGMP), they increase the availability of NO produced by the endothelial sytem (2,3). 2. We have developed a simple non-invasive test ( acetylcholine ionyophoresis - ACH Iph), identifying the status of the endothelial system. BY applying this methodolgy to normal subjects as wells as to patients with peripheral arterial disease, diabetes, hypertensive disease and hypercholesterolemia, we will be able to determine if PDE 5 medication, given to the described groups of subjects, will improve their endothelial activity. In the positive case it will represent a significant improvement of patient's cardiovascualr risk factors.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 1.内皮素是血管系统的重要组成部分，并且已经证明它在控制心血管风险因素中起着重要作用（1）。磷酸二酯酶5型（PDE 5）物质已被证明，通过灭活环鸟苷磷酸（cGMP），它们增加了内皮系统产生的NO的可用性（2，3）。 2.我们已经开发了一种简单的非侵入性测试（乙酰胆碱离子电泳- ACH Iph），确定内皮系统的状态。通过将该方法应用于正常受试者以及患有外周动脉疾病、糖尿病、高血压疾病和高胆固醇血症的患者，我们将能够确定给予所述受试者组的PDE 5药物是否会改善其内皮活性。在积极的情况下，它将代表患者的心血管风险因素的显着改善。